CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
1. Cumberland Pharmaceuticals will release Q3 2024 results on Nov. 7. 2. A conference call will follow at 4:30 p.m. ET for discussion. 3. Company focuses on unique products for hospital and oncology markets. 4. Current FDA-approved products include Acetadote and Caldolor injections. 5. Phase II trials are ongoing for ifetroban targeting serious conditions.